Navigation Links
Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
Date:9/8/2011

LA JOLLA, Calif., Sept. 8, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the presentation of recent advances in its microRNA therapeutic preclinical programs for the treatment of metabolic diseases and cancer. Specifically, Neil W. Gibson, Ph.D., Regulus' chief scientific officer will provide updates on the company's programs targeting microRNA-33 and microRNA-21 at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society held Sept. 8–10, 2011, in Copenhagen, Denmark.  In a talk titled "Therapeutic Targeting of microRNAs," Dr. Gibson will present new data demonstrating that the inhibition of microRNA-33 with proprietary oligonucleotide anti-miRs in animal models increased levels of HDL-cholesterol (the 'good' cholesterol) and reduced levels of triglycerides.  Additional preclinical data presented by Regulus confirmed that microRNA-21 is upregulated in human cancers and that microRNA-21 inhibition impacts tumor burden and significantly increases survival in preclinical models of hepatocellular carcinoma.

"Our exciting data show that inhibiting dysregulated microRNAs with our proprietary anti-miR oligonucleotides are effective at altering disease pathogenesis in animal models and provide us confidence to move these programs forward into clinical development," said Dr. Gibson. "Indeed, anti-miRs targeting miR-33 show promise as a novel strategy for treatment of cardiovascular disease and metabolic syndrome while anti-miRs targeting miR-21 demonstrate robust efficacy in pre-clinical tumor models."

Data updates will be made on the following programs:

miR-33. Regulus is developing microRNA therapeutics targeting miR-33 using proprietary chemically modified anti-miR oligonucleotides delivered systemically. microRNA-33a and b (miR-33a/b), whi
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Auxilium Pharmaceuticals, ... company, today confirmed that Auxilium has received an unsolicited, ... ENDP ) to acquire all of the outstanding shares ... per share in cash and Endo stock, subject to ... the unsolicited, non-binding proposal that Auxilium received from Endo ...
(Date:9/16/2014)... Massachusetts , 17 settembre 2014 ... annunciato oggi il lancio in Europa del Tomcat, ... Tomcat è una piattaforma multifunzionale completamente automatizzata, progettata ... le inefficienze ed i rischi di errore legati ... automazione dello strumento Tomcat di Hologic riduce il ...
(Date:9/16/2014)... 3SBio Inc., ("3SBio") a leading biotechnology ... focusing on researching, developing, manufacturing and marketing biopharmaceutical ... an exclusive license agreement with JenKem Technology Co., ... in Mainland China of PEG-irinotecan, a long-acting polymer-drug ... over-expressed in many solid tumors, including colorectal, ovarian, ...
Breaking Medicine Technology:Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5
... GlaxoSmithKline (NYSE: GSK ) confirmed today that a joint ... allow Avandia to remain on the market. Committee members voted for recommendations ... label with additional warnings and restrictions (20) to withdrawal from the U.S. ... , ...
... Services announced today  that the American Board of Radiology (ABR) has qualified ... therapy--as a Practice Quality Improvement (PQI) for the purpose of Maintenance of ... , With ... audit of their beam data through the use of a web portal: ...
Cached Medicine Technology:GlaxoSmithKline Statement in Response to FDA Advisory Committees' Vote on Safety of Avandia® (rosiglitazone) 2GlaxoSmithKline Statement in Response to FDA Advisory Committees' Vote on Safety of Avandia® (rosiglitazone) 3GlaxoSmithKline Statement in Response to FDA Advisory Committees' Vote on Safety of Avandia® (rosiglitazone) 4eDataAudit Receives Approval from the American Board of Radiology 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 With ... have special functions of adjusting human body physiology, ... won great popularity with a variety of specific ... food in China reached RMB187.4 billion, up 12.0% ... during 2006-2013. , China's health product industry is ...
(Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
(Date:9/17/2014)... 17, 2014 Researchers say patients with ... least likely to have good outcomes with chemotherapy treatment. ... findings. Click here to read it now. ... Levine Cancer Institute in North Carolina analyzed 30 published ... the 137 patients with sarcomatoid mesothelioma had ...
(Date:9/17/2014)... 17, 2014 There’s something changing ... girls of all ages an all-natural option for ... by women, for women, announces the launch of ... to relieve the symptoms commonly associated with ... , As a lifelong health enthusiast and ...
(Date:9/17/2014)... September 17, 2014 Request A Test ... testing, is offering 10% off drug testing through ... all drug tests, including those ordered by employers for workplace ... advantage of this discount by using promo code DRUG10 when ... in positives on workplace drug testing, especially for marijuana or ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Doctors Find Lower Treatment Response in Those with Rare Type of Mesothelioma, According to Surviving Mesothelioma 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
... Jeff Klein Renowned for IVF Success, NEWBURGH, ... clinical affiliate of The Mount Sinai Hospital, is ... region with the addition of,Reproductive Endocrinologist Jeffrey Klein, ... medical director of the Westchester division of,Reproductive Medicine ...
... PITTSBURGH and PLYMOUTH MEETING, Pa., March 12 ... Maintenance,Management Systems (CMMS) for the healthcare industry and ... approaches to improving,patient care, announce the availability of ... and recall alert applications., This new ...
... air purifier,delivers cleaner and healthier air. It effectively ... pollutants that affect us every day at work ... value through the unbeatable,combination of consumer benefits., ... and Ozone Cause Severe Health Problems, Millions ...
... University of Warwick has uncovered exactly how the bacterium ... The same research could also open up MRSA to ... designer antibiotics to use against a range of other ... fatal pneumonia infections a year in children. In the ...
... . , Quebec City, March 12, 2008A research ... identified genetic markers that allow the selection of eggs ... after in vitro fertilization (IVF). This finding could both ... diminish the risk of multiple pregnancies. The details of ...
... 12, 2008 AstraZeneca (NYSE: AZN) announced today that ... III studies for vandetanib, the companys investigational, once-daily oral ... lung cancer (NSCLC). The two studies ZODIAC (ZACTIMA ... and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) ...
Cached Medicine News:Health News:SLCH Brings Infertility Specialist to Region 2Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 2Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 3Health News:LightAir Cleans the Air From the Smallest and Most Dangerous Particles Without Generating Ozone 2Health News:Research could put penicillin back in battle against antibiotic resistant bugs that kill millions 2Health News:Researchers develop a method to select eggs with the best chance of leading to successful pregnancy 2Health News:Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib 2
... Multifunctional instrumentation, capable of ... tissue by means of ultra-sonic ... on organs, and, in particular, ... advantages of tissue-selection and non-traumatic ...
... expect from the long-established Selector Ultrasonic ... integrated circuitry and the small, ergonomic ... surgical techniques, ultrasonic surgery selectively dissects ... as nerves and blood vessels relatively ...
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 9.0 mm and length 7.5 mm....
Medicine Products: